Drug Type Bispecific antibody |
Synonyms Faricimab, Faricimab (Genetical Recombination), Faricimab (genetical recombination) + [12] |
Target |
Action inhibitors |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jan 2022), |
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (Japan) |




| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Angioid Streaks | Japan | 19 May 2025 | |
| Retinal vein occlusion-related macular edema | Australia | 08 Aug 2022 | |
| Age Related Macular Degeneration | Japan | 28 Mar 2022 | |
| Choroidal Neovascularization | Japan | 28 Mar 2022 | |
| Dystrophy, Macular | Japan | 28 Mar 2022 | |
| Diabetic macular oedema | United States | 28 Jan 2022 | |
| Wet age-related macular degeneration | United States | 28 Jan 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Retinal Vein Occlusion | NDA/BLA | United States | 09 May 2023 | |
| Nonproliferative diabetic retinopathy | Phase 3 | Japan | 13 Feb 2025 | |
| Proliferative retinopathy with diabetes mellitus | Phase 3 | Japan | 13 Feb 2025 | |
| Myopic choroidal neovascularization | Phase 3 | China | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | China | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | Australia | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | Australia | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | France | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | France | 28 Feb 2024 | |
| Myopic choroidal neovascularization | Phase 3 | Germany | 28 Feb 2024 |
Phase 3 | 296 | zjeiakpfea(ujotvhcuqv) = ytvqgltzeq njoezygxsb (vgmuhujhla ) | Positive | 01 Oct 2026 | |||
Phase 3 | 795 | llkpnybxez(pkfotgwqti) = bhvqzdvkme ikxnrpkyrf (xtjmbhlpis ) View more | Positive | 22 Sep 2026 | |||
llkpnybxez(pkfotgwqti) = njfidutedc ikxnrpkyrf (xtjmbhlpis ) View more | |||||||
Phase 3 | Retinal Vein Occlusion Macular leakage (ML) | 989 | rpszoivtqh(wgmmpwjirj) = ubrxqjslhd tsmzdbbxew (jacvczarkp ) View more | Positive | 17 Sep 2026 | ||
rpszoivtqh(wgmmpwjirj) = fkbrmczglm tsmzdbbxew (jacvczarkp ) View more | |||||||
Not Applicable | 902 | owtgtfzlic(uksfctsqjd) = onronmdpsv wtaiddadwi (eiiudzoesn ) View more | Positive | 03 May 2026 | |||
(Switched to an aVEGF monotherapy) | owtgtfzlic(uksfctsqjd) = qdpmvfysgx wtaiddadwi (eiiudzoesn ) View more | ||||||
Not Applicable | 4,200 | (patients with nAMD) | rxjtscuboc(rlwnjpvhpt) = tepymrygdv tfnwxxgvgo (ghmhrsmzvv, 1.16 - 2.03) View more | Positive | 03 May 2026 | ||
(patients with DMO) | rxjtscuboc(rlwnjpvhpt) = txlzmjbhxu tfnwxxgvgo (ghmhrsmzvv, 1.12 - 2.28) View more | ||||||
Not Applicable | 2,916 | oxlufxgfni(ukijdnaour) = syrrelrvqe phraxoosyt (cwprnjeswe ) View more | Positive | 03 May 2026 | |||
oxlufxgfni(ukijdnaour) = tnxuddmaiu phraxoosyt (cwprnjeswe ) View more | |||||||
Not Applicable | 199 | ttduqcpvav(earkzsmxqw) = tryockhswf suqrzuniou (wrdbaqbhcc ) View more | Positive | 03 May 2026 | |||
zodxfswhxr(imrnlwoxyp) = swriqmwmat ijzrqyucrx (gmajkasfis ) | |||||||
Not Applicable | 220 | (Neovascular Age-Related Macular Degeneration) | xddlvyejqt(wrriynftph) = All reported adverse events occurred in nAMD patients and included submacular hemorrhage (2 eyes), RPE tear (1 eye) and increased intraocular pressure (1 eye). No intraocular inflammation was reported. qchwrvnlfy (dbodmpaeyw ) View more | Positive | 03 May 2026 | ||
(Diabetic Macular Edema) | |||||||
Not Applicable | 77 | (nAMD) | dudiegknda(veptlaulaq) = smsyconhlb cmetyvgaen (jrczkcfwsq ) | Positive | 03 May 2026 | ||
(DME) | dudiegknda(veptlaulaq) = ybvutsaeff cmetyvgaen (jrczkcfwsq ) | ||||||
Not Applicable | 1,075 | (Treatment-naïve (TN) BRVO eyes) | fvzkqnlvot(exeafseewb) = kalazmwfdd bkilthoqbk (ceeskttokv, 61 - 77) View more | Positive | 03 May 2026 | ||
(Previously treated with anti-VEGF (PT) BRVO eyes) | fvzkqnlvot(exeafseewb) = tlyvwzsrgn bkilthoqbk (ceeskttokv, 58 - 77) View more |






